MSB 1.29% $1.18 mesoblast limited

The Lvad trial has Rmat designation which is similiar to...

  1. 192 Posts.
    lightbulb Created with Sketch. 137
    The Lvad trial has Rmat designation which is similiar to breakthrough status.
    A trial that passes phase one with sufficient safety and the chances of efficacy can be approved by FDA
    There will be follow up in either one of a confirming trial, following real world cases or both
    Check out RMAT guidlines
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.18
Change
0.015(1.29%)
Mkt cap ! $1.347B
Open High Low Value Volume
$1.15 $1.20 $1.15 $4.551M 3.886M

Buyers (Bids)

No. Vol. Price($)
2 98246 $1.17
 

Sellers (Offers)

Price($) Vol. No.
$1.18 19079 2
View Market Depth
Last trade - 16.10pm 16/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.